Wall Street analyst estimates for Inovio Pharmaceuticals, Inc. (INO): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 9 |
| Hold | 6 |
| Sell | 2 |
| Strong Sell | 0 |
| Total analysts | 17 |
| Avg rating (1-5) | 0.41 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-10 | $-0.20 | ||
| 2026-08-12 | $-0.07 | $-0.22 | +67.7% |
| 2026-05-13 | $-0.28 | $-0.35 | +20.0% |
| 2026-03-12 | $0.06 | $-0.37 | +116.2% |
| 2025-11-10 | $-0.87 | $-0.42 | -106.3% |
| 2025-08-12 | $-0.61 | $-0.63 | +3.2% |
| 2025-05-13 | $-0.51 | $-0.74 | +31.1% |
| 2025-03-18 | $-0.69 | $-0.87 | +20.7% |
Valuation Ratios
| Price / Book | 2.72 |
| EV / EBITDA | -0.57 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $35.4M | $42.2M | $30.5M | $4.1M | $7.4M | $1.8M | $10.3M | $832010 | $217756 | $65343 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | $35.4M | $42.2M | $30.5M | $4.1M | $7.4M | $1.8M | $10.3M | $832010 | $217756 | $65343 |
| Research & Development | $88.7M | $98.6M | $95.3M | $88.0M | $94.2M | $249.2M | $187.7M | $86.7M | $75.6M | $54.2M |
| Selling, General & Admin | $23.9M | $28.3M | $29.3M | $27.2M | $37.2M | $53.8M | $90.2M | $47.6M | $37.0M | $32.7M |
| Operating Expenses | $112.6M | $126.9M | $124.6M | $115.2M | $131.5M | $303.0M | $277.8M | $144.8M | $112.6M | $86.9M |
| Operating Income | -$76.2M | -$83.6M | -$94.1M | -$111.1M | -$124.1M | -$301.2M | -$267.6M | -$143.9M | -$112.4M | -$86.8M |
| EBITDA | -$74.1M | -$84.7M | -$89.8M | -$107.3M | -$149.6M | -$296.6M | -$270.9M | -$130.4M | -$103.9M | -$82.0M |
| Interest Expense | $139249 | $25933 | 0 | $7.9M | $8.7M | $1.9M | $1.3M | $1.2M | $177833 | 0 |
| Pre-tax Income | -$73.7M | -$88.2M | -$94.8M | -$120.8M | -$167.5M | -$303.7M | -$279.8M | -$135.1M | -$107.3M | -$84.9M |
| Income Tax | 0 | 0 | $2.2M | -$257335 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$73.7M | -$88.2M | -$97.0M | -$119.4M | -$166.4M | -$303.7M | -$279.8M | -$135.1M | -$107.3M | -$84.9M |
| EPS | $-1.01 | $-1.08 | $-1.05 | $-0.97 | $-1.07 | $-1.42 | $-14.07 | $-6.09 | $-3.95 | $-1.81 |
| EPS (Diluted) | $-1.01 | $-1.08 | $-1.05 | $-0.97 | $-1.07 | $-1.42 | $-14.07 | $-6.09 | $-3.95 | $-1.81 |
| Shares Outstanding (Diluted) | $6.1M | $6.8M | $7.7M | $8.2M | $12.9M | $17.4M | $19.9M | $22.2M | $27.2M | $46.9M |
Price
| Price | $1.15 |
| Market Cap | $79M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ABOS · ACTU · AGEN · ALEC · FATE · IRD · MCRB
Explore sector: Healthcare · Biotechnology
More sections of INO: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks